INTERVIEW: JnJ Medical India's Chief On The 'Middle India' Push
This article was originally published in Clinica
Executive Summary
Johnson &Johnson Medical India is implementing a clutch of new go-to-market approaches and managing director Sushobhan Dasgupta expects these to increase the "depth and breadth" of the US multinational's coverage across the country. J&J is the number one medical devices company in India.
You may also be interested in...
How J&J Hopes To Disrupt India's Diabetes Care Paradigm
Sushobhan Dasgupta, managing director of Johnson & Johnson Medical India, discusses how J&J's new go-to-market strategies are playing out, the role of e-commerce for medical devices in India, and how the company is leveraging its capabilities to provide solutions for the whole diabetic care pathway.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet